Anthropic unveiled Claude Science, a standalone product designed to support scientific research, at an event for pharmaceutical executives and biotech researchers. Now available to all paid Claude subscribers, the platform aims to automate complex tasks in computational biology and drug development, following the model of Claude Code for software engineering.
Claude Science features autonomous capabilities and computing cluster integration
Unlike previous life science plugins, Claude Science is a full-fledged product. According to Eric Kauderer-Abrams, Anthropic's head of life sciences, it can execute high-level instructions and access tools for molecular biology, chemistry, and genetics. It also helps scientists run code on powerful computing clusters and prioritizes reproducibility, enabling verification of every figure or result.
Sponsored Protocol
Competing with Google DeepMind and focusing on rare diseases
Anthropic aims to fill the gap left by Google DeepMind in scientific AI. While DeepMind won a Nobel Prize for AlphaFold, Anthropic recently attracted researcher John Jumper. The platform has already been used to identify new drug candidates for phenylketonuria, a rare genetic disease. Anthropic will also use Claude Science for internal research on neglected diseases, combining humanitarian goals with potential lucrative contracts from the pharmaceutical industry.
Sponsored Protocol
Impact on small businesses and regulatory context
The launch of Claude Science occurs amid evolving AI regulations. Recently, OpenAI tightened access in Europe, hurting Italian SMEs. Additionally, Trump dropped restrictions on Anthropic's models, signaling a changing regulatory climate. Claude Science's new capabilities could accelerate pharmaceutical research but require attention to ethical and regulatory aspects.
For further reading, see the original article on MIT Technology Review.
